Bedard P - Search Results

1

Management of small HER2 overexpressing tumours.

Templeton A, Ocaña A, Seruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Templeton A, et al. Among authors: bedard p. Breast Cancer Res Treat. 2012 Nov;136(1):289-93. doi: 10.1007/s10549-012-2236-9. Epub 2012 Sep 6. Breast Cancer Res Treat. 2012. PMID: 22956007

2

Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?

Bedard PL, Freedman OC, Howell A, Clemons M. Bedard PL, et al. Breast Cancer Res Treat. 2008 Apr;108(3):307-17. doi: 10.1007/s10549-007-9606-8. Epub 2007 May 22. Breast Cancer Res Treat. 2008. PMID: 18351454 Review.

3

Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.

Bedard PL, Piccart-Gebhart MJ. Bedard PL, et al. Clin Breast Cancer. 2008 Dec;8 Suppl 4:S157-65. doi: 10.3816/CBC.2008.s.012. Clin Breast Cancer. 2008. PMID: 19158036 Review.

4

Luminal-B breast cancer and novel therapeutic targets.

Tran B, Bedard PL. Tran B, et al. Breast Cancer Res. 2011;13(6):221. doi: 10.1186/bcr2904. Epub 2011 Nov 30. Breast Cancer Res. 2011. PMID: 22217398 Free PMC article. Review.

5

Benefits and harms of detecting clinically occult breast cancer.

Amir E, Bedard PL, Ocaña A, Seruga B. Amir E, et al. J Natl Cancer Inst. 2012 Oct 17;104(20):1542-7. doi: 10.1093/jnci/djs394. Epub 2012 Sep 17. J Natl Cancer Inst. 2012. PMID: 22988040

6

Personalized medicine for metastatic breast cancer.

Chen TW, Bedard PL. Chen TW, et al. Curr Opin Oncol. 2013 Nov;25(6):615-24. doi: 10.1097/CCO.0000000000000015. Curr Opin Oncol. 2013. PMID: 24097103 Review.

7

Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Razak AR. Manji A, et al. J Clin Oncol. 2013 Nov 20;31(33):4260-7. doi: 10.1200/JCO.2012.47.4957. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127441 Review.

8

Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Vera-Badillo FE, et al. Among authors: bedard pl. J Natl Cancer Inst. 2014 Jan;106(1):djt319. doi: 10.1093/jnci/djt319. Epub 2013 Nov 22. J Natl Cancer Inst. 2014. PMID: 24273215 Review.

9

A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.

Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, Douglas S, Wang L, Siu LL, Tannock IF, Bedard PL. Brana I, et al. Invest New Drugs. 2014 Dec;32(6):1269-77. doi: 10.1007/s10637-014-0159-5. Epub 2014 Sep 12. Invest New Drugs. 2014. PMID: 25213162 Clinical Trial.

10

Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs.

Tibau A, Bedard PL, Srikanthan A, Ethier JL, Vera-Badillo FE, Templeton AJ, Ocaña A, Seruga B, Barnadas A, Amir E. Tibau A, et al. J Clin Oncol. 2015 Jan 1;33(1):100-6. doi: 10.1200/JCO.2014.57.8898. Epub 2014 Nov 10. J Clin Oncol. 2015. PMID: 25385736

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

650 results

Search Page

Filters